Welcome to our dedicated page for 20/20 Biolabs news (Ticker: AIDX), a resource for investors and traders seeking the latest updates and insights on 20/20 Biolabs stock.
20/20 BioLabs news covers the commercialization of its OneTest laboratory blood-test families, including OneTest for Cancer and OneTest for Longevity. Recurring developments include cancer screening programs, practitioner-channel distribution, AI-enabled chronic disease risk assessment, biomarker technology updates, and laboratory operations tied to its CAP-accredited and CLIA-licensed facility.
Company updates also report financial results, Nasdaq public-company milestones, material license or collaboration agreements, and customer-market activity in public-sector, occupational health, functional medicine, and direct-to-consumer channels.
20/20 BioLabs (Nasdaq: AIDX) launched OneTest for Longevity, a commercial blood-test solution available Feb 25, 2026 that combines inflammatory biomarkers, dietary and lifestyle inputs, and curated research to estimate chronic disease risk and offer personalized dietary guidance.
The platform uses IBM watsonx.ai and IBM Granite 4.0 foundation models, with Docling reportedly processing nutritional research 30x faster. The test is offered as a laboratory-developed test (LDT) in CLIA-licensed, CAP-accredited labs and has not sought or received FDA approval.